There was an independent arm's-length group of advisers—the expert advisory committee and vaccine task force. They assessed all the different technologies that were available. They recommended that Canada pursue a portfolio approach to conclude APAs. That portfolio, the seven APAs that we did conclude, comprised a wide variety of technologies ranging from mRNA to protein subunit to viral vector-based vaccines and a variety of platforms, including the plant-based innovative technologies of Medicago.
On December 6th, 2023. See this statement in context.